Physician profile
Rohan Kapoor
NPI 1508275181
$17,402.43
in general payments reported to CMS, 2019-2025
46 companies · $6,751 in 2025
The $6,751 reported for 2025 was more than what 96% of Pain Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,349 · 2020: $571 · 2021: $1,950 · 2022: $1,925 · 2023: $2,525 · 2024: $2,331 · 2025: $6,751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,192 · Travel and Lodging: $3,415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,192.23 |
| Travel and Lodging | $3,415.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,808.50 | 2019-2025 | General - Therapies, General - Pain Management |
| Nevro Corp. | $3,754.97 | 2021-2024 | Senza |
| Medtronic, INC. | $2,399.78 | 2021-2025 | Kyphon Express II Kyphopak Tray, Intellis Adaptivestim |
| Globus Medical, INC. | $1,841.03 | 2025 | Senza, Excelsius Gps, Vyrsa V1 |
| Medtronic USA, INC. | $1,279.77 | 2019-2020 | |
| Abbvie INC. | $504.81 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $486.70 | 2021-2025 | Belbuca, Xtampza |
| Abbott Laboratories | $375.24 | 2020-2025 | Eterna, Proclaim |
| Foundation Fusion Solutions, LLC | $333.05 | 2021-2022 | |
| Vertos Medical, INC. | $293.64 | 2021-2022 | |
| Amgen INC. | $285.81 | 2021-2022 | |
| Lilly USA, LLC | $198.19 | 2021-2023 | Emgality, Reyvow |
| Grt US Holding, INC. | $151.24 | 2021 | |
| Pfizer INC. | $142.48 | 2020-2025 | |
| Fidia Pharma USA INC. | $126.61 | 2023-2025 | Hymovis, Triluron, Hyalgan |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $123.70 | 2021 | |
| Spr Therapeutics, INC | $117.46 | 2023-2024 | Sprint Pns System |
| Si-Bone, INC. | $115.97 | 2024-2025 | |
| Allergan, INC. | $88.82 | 2021-2022 | |
| Nalu Medical, INC. | $65.70 | 2021-2025 | Nalu Neurostimulation System |
| Ibsa Pharma INC. | $59.67 | 2023-2025 | Tirosint, Licart, Tirosint |
| Pacira Pharmaceuticals Incorporated | $59.29 | 2023 | Iovera, Zilretta |
| Saluda Medical Americas, INC. | $56.91 | 2023 | Evoke Scs |
| Bioventus LLC | $54.98 | 2021-2025 | Xcell |
| Merz Pharmaceuticals, LLC | $52.35 | 2025 | Xeomin |
| Avanos Medical | $50.92 | 2024-2025 | Genvisc 850 Sodium Hyaluronate |
| Spinal Simplicity, LLC | $50.47 | 2024 | Ha Minuteman G3-R |
| Supernus Pharmaceuticals, INC. | $47.64 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $47.53 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $43.19 | 2023 | Seglentis |
| Ipsen Biopharmaceuticals, INC | $38.83 | 2024 | Dysport |
| Almatica Pharma LLC | $36.53 | 2022 | |
| Currax Pharmaceuticals LLC | $33.84 | 2021-2023 | Contrave |
| Depuy Synthes Sales INC. | $33.05 | 2024 | Orthovisc, Monovisc |
| Valinor Pharma, LLC | $30.85 | 2025 | Movantik |
| Uswm, LLC | $30.08 | 2021-2022 | |
| Neuros Medical, INC. | $25.53 | 2025 | Altius |
| Azurity Pharmaceuticals, INC. | $21.76 | 2022 | |
| Stratus Medical, LLC | $20.00 | 2023 | Nimbus |
| Painteq LLC | $19.08 | 2024 | Painteq |
| Orthofix Medical, INC. | $18.70 | 2021 | |
| Genentech USA, INC. | $17.16 | 2020 | |
| Scilex Pharmaceuticals INC. | $16.12 | 2024 | |
| Pacira Therapeutics, INC. | $15.53 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.57 | 2021 | |
| Merit Medical Systems INC | $14.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohan Kapoor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.